Additional data on BerGenBio’s selective AXL inhibitor bemcentinib to be presented at the 2023 ESMO meeting
BERGEN, Norway, October 16, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists (ESMO) Annual Meeting 2023, to be held October 20-24 in Madrid. Enriqueta Felip, M.D., Ph.D., Head of the Thoracic Cancer Unit at Vall d’Hebron University Hospital, Spain will present the following